Kornimate/medical-research-clean huggingface dataset:
a study:the different outcomes between natural cycle and hormone replacement cycle in fet

Conditions: Infertility

Summary: there are three main cycle regimens used for endometrial preparation for frozen embryo transfer（fet）: natural cycles (nc) with/without ovulation triggering, hormone replacement therapy cycles (hrt) in which the endometrium is artificially prepared by estrogen and progesterone hormones with/without a gonadotrophin releasing hormone agonist (gnrh-a) down regulation, and ovulation induced cycles (oi) in which follicular development is supported with increasing doses of gonadotrophin hormones and ovulation is induced. at present, there is still no sufficient evidence that which kind of fet cycle regimen to plan more advantage. the purpose of this study was to compare the pregnancy outcome of nc-fet to that of hrt-fet in women with regular cycles.

this study is a prospective randomized controlled trial. patients with regular cycles undergoing fet in reproductive medicine renter of sun yat-sen memorial hospital will be recruited，who should not be elder than 40 and had more than 3 frozen embryos. they will be randomized to receive either the nc-fet cycle (group nc-a) or the hrt-fet cycle (group hrt-b). in group nc-a, the ovulation is monitored spontaneously or induced by human chorionic gonadotropin(hcg) when the dominant follicle is larger than 18mm without luteinizing hormone surge(lh). transfer of thawed embryos will be performed 4 days after lh /hcg administration or 3 days after ovulation is observed. in group hrt-b, oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. if the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. transfer of thawed embryos will be performed 3 days later. this study was approved by the reproductive medicine ethics committee of sun yet-sen memorial hospital.

Eligibility criteria:
inclusion criteria: * age forty years old or less * has regulation menstruation (cycle 24-35 days) or previous data suggest that normal ovulation * frozen embryos number more than three exclusion criteria: * has chocolate cyst or adenomyosis of uterus * clear hydrosalpinx * uterine scar or intrauterine adhesion and endometrial thickness \<7mm before ovulation * recur thick endometrium（\<7mm） * repeated implantation failure（≥3 times） * cancel the cycle because of having no dominant follicle in the nc+fet before or the growth of endometrium not good in the hrt+fet before

Keywords: endometrium preparation protocols frozen-thawed embryo transfer natural cycles hormone replacement therapy cycles randomized controlled trial
blood immunophenotyping in staging of indolent b-cell lymphomas v1.0

Conditions: Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL)

Summary: to determine whether peripheral blood flow cytometry can reduce or replace invasive bone marrow examinations in patients with slow growing lymphomas.

this study will determine whether peripheral blood flow cytometry can reduce or replace invasive bone marrow examinations in patients with slow growing lymphomas. patients with certain types of slow growing (indolent) lymphomas, including the most common sub-type, follicular lymphoma, require a bone marrow examination for staging of their lymphoma. this provides prognostic information and can be important for planning treatment. however, despite the use of local anaesthetic, and in some cases sedation, bone marrow examinations can cause pain and discomfort to patients. complications are rare but include risk of bleeding, infection and even nerve damage. flow cytometry of peripheral blood samples can detect low levels of circulating lymphoma cells. a previous study has demonstrated that detection of lymphoma cells by peripheral blood flow cytometry has a good correlation with bone marrow involvement. this study will seek to find if this correlation is evident in a larger, statistically significant patient cohort. depending on the study results, invasive and painful bone marrow procedures could potentially be reduced or eliminated in patients with certain slow growing lymphomas. patients diagnosed with follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma and being treated at the royal marsden nhs foundation trust will be eligible for this study. participation in the study will require one peripheral blood sample to be taken before the patient's routine bone marrow biopsy. the study is expected to last between 2 - 3 years for data collection of 108 samples.

Eligibility criteria:
inclusion criteria: * individuals ≥18yrs of age * able to provide informed written consent * patients with a diagnosis of follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma requiring staging or re-staging as part of clinical management * pre-transplant bone marrow assessment * high grade transformation associated with the above lymphomas will be allowed. exclusion criteria: * patients with a histological diagnosis other than those mentioned above or those diagnosed with 2 or more different lymphomas, excluding transformed lymphoma. * patients not fit enough to undergo bone marrow examination.
seasickness susceptability and vestibular time constant

Conditions: Seasickness

Summary: participants were selected from the military navy crewmembers prior to commencing of active sailing. a vestibular time constant was calculated based on velocity step testing on a rotatory chair at baseline, 3 months and 6 month following active sailing duty. a seasickness questionnaire (wiker) was completed during follow-up visits. study participants were divided to three groups based on wiker score - susceptible , non-susceptible and habituating. vestibular time constant was compared between study groups.


Eligibility criteria:
inclusion criteria: * healthy male navy sailors in basic training exclusion criteria: * history of hearing loss * otoscopic findings of ear pathology * an implanted electrode * a finding of vestibulopathy upon otoneurological examination - * discontinuation of active sailing for any reason during study follow-up * withdrawal of informed consent.
antidiuretic function before and during treatment with sglt2 inhibitors

Conditions: Diabetes Mellitus, Type 2; Arterial Hypertension; Body Weight Changes

Summary: subjects treated with canagliflozin, dapagliflozin and empagliflozin obtained improvement on blood pressure values, body weight and cardiovascular mortality but pathophysiological explanations of these effects are not yet known.

the pathophysiological explanations of the cardiovascular improvement of patients treated with sglt2i are not yet known: osmotic diuresis and natriuresis, direct effects of weight reduction, increased in nitric oxide release, oxidative stress reduction, local renin-angiotensin-aldosterone system (raas) inhibition are the supposed mechanism. in the literature the diuretic effect of sglt2i therapy seems to be even stronger than thiazide or thiazide-like drugs. however, it is not defined the role of sglt2i on antidiuretic function (raas, brain natriuretic peptide-bnp and antidiuretic hormone-adh). defining this relation could be important for: * knowing effect of sglt2i on raas (drugs interferences are important particularly during case detection of primary aldosteronism); * discovering antidiuretic response to sglt2i treatment and interactions between raas, bnp and adh on the volume improvement induced by this new antidiabetic drugs. in addition the aim of the study is to define effect of treatment on blood pressure and body composition.

Eligibility criteria:
inclusion criteria: * diabetic patients; * clinical indication to sglt2i therapy. exclusion criteria: * signs and symptoms of poor glycemic control (polydipsia, polyuria and weight loss); * hba1c \>10% or 86 mmol/mol; * body mass index (bmi) \> 40 kg/m2; * personal history of primary and secondary aldosteronism; * personal history of heart failure; * personal history of acute kidney injury; * personal history of chronic kidney disease; * personal history of liver cirrhosis; * personal history of protein-wasting syndrome; * personal history of renin secreting tumor; * personal history of diabetes insipidus; * personal history of syndrome of inappropriate antidiuresis (siad); * personal history of hypocortisolism and hypercortisolism; * therapy with angiotensin converting enzyme inhibitors; * therapy with angiotensin receptor blockers; * therapy with renin inhibitors; * therapy with beta-blockers; * therapy with alfa2-receptors agonists; * therapy with calcium channel blockers; * therapy with diuretics; * therapy with mineralocorticoid receptor antagonists; * therapy with non steroidal and steroidal anti-inflammatory drugs.

Keywords: sodium-glucose transporter 2 inhibitors renin-angiotensin system vasopressin natriuretic peptide, brain blood pressure body composition diabetes mellitus, type 2
metformin in safety and efficacy in gouty patients

Conditions: Gout

Summary: the most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. gouty patients frequently have excruciating pain and swelling in their joints. gout is linked to decreased health-related quality of life and functional disability. gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients


Eligibility criteria:
inclusion criteria: * gouty patients clinically diagnosed as gouty arthritis based on the american college of rheumatology/european league against rheumatism criteria of gout. exclusion criteria: * systemic disorders such as cardiovascular, neurological, coronary artery disease. * hypertension, hyperlipidemia, diabetes mellitus, active infections. * other inflammatory or autoimmune diseases. * patients on biologics, * cases with hypersensitivity to metformin and those with impaired liver and kidney functions.
effect of the intra-abdominal pressure on the risk of delirium in mechanically ventilated patients.

Conditions: Delirium; Intraabdominal Hypertension; Mechanical Ventilation Complication

Summary: intra-abdominal hypertension (iah) and delirium are serious, high-frequency complications in intensive care unit (icu) patients. the consequences of the complication range from high morbidity and mortality to a greater need for nursing care. we hypothesize that there could be a correlation between iah and incidence of delirium.


Eligibility criteria:
inclusion criteria: * patients of both genders on mechanical ventilation exclusion criteria: * age under 18 years, use of muscle relaxants, abdominal operation within the previous 3 months, acute peritonitis, and abdominal mass, acute injury to the urinary bladder, acute cystitis, neurogenic bladder, pelvic hematoma, and pelvic fracture.
ai in outpatient practice for diagnosing aortic stenosis and diastolic dysfunction

Conditions: Aortic Stenosis; Diastolic Dysfunction

Summary: two recently developed artificial intelligence-enabled electrocardiogram (ai-ecg) models have been developed to detect aortic stenosis (as) and diastolic dysfunction (dd). ai-ecg for as has a sensitivity of 78% and specificity of 74%, and ai-ecg for dd has a sensitivity of 83% and specificity of 80%. however, these models have never been prospectively applied to diagnose as or dd, which may be useful for patients and providers from a diagnostic and prognostic perspective and especially in settings where access to higher- level medical care is limited. in this study, we aim to determine the clinical utility of these ai-ecg models by prospectively applying them to an outpatient cohort and then completing a focused point-of-care ultrasound to evaluate those who are ai-ecg positive for as and dd.


Eligibility criteria:
inclusion criteria: * ≥ 60 years of age must have a clinical scheduled ecg performed. exclusion criteria: * \< 59 years of age * is not scheduled for a clinical ecg * unable to provide consent.
a psoriasis plaque test trial with lp0113 spray in patients with psoriasis vulgaris (lp0113-1123)

Conditions: Skin and Connective Tissue Diseases

Summary: the purpose of this study is to evaluate the anti-psoriatic effect of lp0113 aerosol spray compared to daivobet® gel, leo 90100 aerosol foam, betamethasone dipropionate in the aerosol spray vehicle, calcipotriol in the aerosol spray vehicle and aerosol spray vehicle.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent has been obtained * subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs and/or trunk. the lesions must have a total size suitable for application of 6 different products. * age 18 years or above * outpatients * female subjects must be of either * non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or, * child-bearing potential provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy. exclusion criteria: * female subjects who are breast feeding * systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation: * etanercept - within 4 weeks prior to randomisation and during the trial * adalimumab, infliximab - within 8 weeks prior to randomisation and during the trial * ustekinumab - within 16 weeks prior to randomisation and during the trial * other products - within 4 weeks/5 half-lives prior to randomisation and during the trial (whichever is longer) * systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4-week period prior to randomisation and during the trial, * subjects using phototherapy within the following time periods prior to randomisation and during the trial: * puva: 4 weeks * uvb: 2 weeks * subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the trial: * potent or very potent (who group iii-iv) corticosteroids * subjects using one of the following topical drugs for the treatment of psoriasis within 2 weeks prior to randomisation and during the trial: * who group i-ii corticosteroids (except if used for treatment of scalp and/or facial psoriasis) * topical retinoids, vitamin d analogues, topical immunomodulators (e.g. calcineurin inhibitors), tar products, salicylic acid * subjects using emollients on the selected plaques within 1 week before randomisation and during the trial * initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, antimalarial drugs, lithium and ace inhibitors) within 2 weeks prior to the randomisation and during the trial * subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

Keywords: psoriasis
utility of ct fluoroscopy guidance during percutaneous sacroplasty with quality of life assessment

Conditions: Sacro-iliac Insufficiency Fractures

Summary: to examine, through retrospective and prospective chart review, the difference in pain and mobility, pre and post treatment, as assessed by the patient's completion of the vas pain scale and roland morris disability questionnaire (rmdq). ct fluoroscopy guidance during percutaneous sacroplasty is an effective treatment for sacro-iliac insufficiency fractures resulting in rapid reduction of pain and improved mobility in patients. this can be effectively assessed using the vas pain scale and rmdq both pre and post procedure.

the purpose of the study is to report the use of ct fluoroscopy guidance during the performance of percutaneous sacroplasty. in addition, clinical results will be reported with the roland morris disability questionnaire(rmdq)pre and post procedure, demonstrating the utility of the rmdq in assessing improvement in patients pain, mobility and ability to perform activities of daily living.

Eligibility criteria:
inclusion criteria: * greater than 18 years of age and treated with or about to be treated with percutaneous ct fluoro-guided sacroplasty, regardless of gender or ethnicity. exclusion criteria: * less than 18 years old * pregnancy * inability to complete forms and surveys
a study of ustekinumab treatment in children with crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\ = 40 kilograms \[kg\] at baseline).


Eligibility criteria:
inclusion criteria: * having at least one icn visit with documented new use of ustekinumab * participants with a documented crohn's disease (cd) diagnosis at the time ustekinumab was initiated (that is, baseline); if diagnosis at baseline is missing, then the diagnosis from previous visit within study window will be utilized * having at least one icn visit prior to the icn visit when ustekinumab is first documented * having received first dose of ustekinumab on or before june 22, 2019 * having provided informed consent for use of icn data for research purposes exclusion criteria: * documented exposure to ustekinumab before enrollment in icn (by chart review)
capsulectomy vs capsulotomy in total hip arthroplasty. clinical outcomes and proprioception evaluation

Conditions: Hip Arthrosis

Summary: the purpose of our study is to evaluate the differences in functional activities and proprioception after surgery in subjects who underwent hip prosthesis implant with capsulotomy or capsulectomy.

concerning hip arthroplasty surgery, in patients affected by coxarthrosis, there are two different techniques: one is capsulectomy and the second one is capsulotomy with repairing the capsule at the end of the procedure. both preserving and excising the capsule are accepted methods and the choice whether repairing the capsule or not is up to the surgeon, since studies have not yet demonstrated the superiority of one of the two techniques. articular capsule has a physiological role in joint stability and proprioception. the presence of proprioceptive nerve endings in hip joint capsule has been observed both in healthy patients and in those affected by coxarthrosis. if capsulectomy is performed during primary hip arthroplasty, the pseudocapsule that is formed in place of the native capsule will not have any active neurophysiological role in the hip. for this reason, investigators compare the two surgical techniques with the purpose of highlighting, if existing, the superiority of one technique on the other in terms of better functional recovery and proprioceptive sensibility.

Eligibility criteria:
inclusion criteria: * elective unilateral primary hip prosthesis utilizing direct anterior approach * age ≥ 18 * signature of the informed consent exclusion criteria: * documented peripheral neuropathies * documented central nervous system diseases that may compromise the balance and/or proprioception * presence of other joint prosthesis in the lower limbs * revision hip arthroplasty * symptomatic osteoarthritis of other joints in the lower limbs (including the controlateral hip) or the spine * bmi \> 35 * systemic diseases or clinical conditions that could interfere with the clinical study * neuromuscular diseases

Keywords: capsulectomy capsulotomy
myocet ® - carboplatine in ovarian cancer in relapse, sensitive to the platinum

Conditions: Ovarian Cancer

Summary: the purpose of this study is to determine the efficacy and the safety of the association of carboplatine and liposomal doxorubicin in patient with ovarian cancer in relapse, sensitive to platin.

in front of a shortage of caelyx, the implementation of an alternative treatment must be considered to treat patients with ovarian cancer in relapse, sensitive to platin: associate the carboplatin with another drug of the family of the doxorubicin: liposomal doxorubicin (myocet®).

Eligibility criteria:
inclusion criteria: * first or second relapse of a carcinoma of the ovary, the fallopian tubes or the peritoneal tissue histological proved. * interval without progress \> 6 months after the last administration of a salt of platinum(deck). * measurable disease (according to the criteria recist 1.1) or an assessable disease according to ca-125 (according to the criteria of the gcig). * satisfactory biological balance sheet(assessment), according to the following criteria: * neutrophiles \> 1,5x 109/l, plaques \> 100 x 109/l, haemoglobin \> 9,0 g/dl. * bilirubine \< 1.5 x lsn (normal superior limit), transaminases and alkaline phosphatase \< 2. 5 x lsn. * creatinin clearance \> 50 ml/min calculated according to the formula of cockroft-gault or mdrd. * performance status \< 2. * life expectancy of at least 12 weeks. * age \> 18 years. * capacity to follow the protocol. * consent signed before any procedure of inclusion. * membership in a national insurance scheme. exclusion criteria: * tumor of mild histology or borderline, or malignant not epithelial tumor of the ovary, the fallopian tubes or the peritoneal tissue(eg. tumor of germ cells, tumor of the sexual cords and the stroma). * history of abdominal or pelvic radiotherapy. * patient having received more than 2 lines of chemotherapy. * patient in 3rd relapse or more. * history of another malignant tumor during the last 5 years, with the exception of a carcinoma in situ by the neck of the womb or by a squamous-cell carcinoma of the skin treated in a adequate way or any solid tumor considered in forgiveness completes without relapse for at least 5 years. * patients having a stubborn illness in the platinum, (eg. progress during the last chemotherapy or in 6 months following the last administration of platinum). * occlusive or sub-occlusive disease or presence of symptomatic intellectual metastases. * heart disorder dissuading the use of an anthracycline. * left venticular ejection fraction (lvef) defined by muga/echo \< 50%. * wait presenting a severe infection. * woman old enough to procreate not using adequate contraceptive method. * concomitant disease not allowing a surgery and/or a chemotherapy. * pathology severe or concomitant not compatible with the taking of the study treatment or the participation of the patient in the study.

Keywords: ovarian cancer in relapse sensitive in platin